Psychedelics not linked to mental health problems or suicidal behavior: A population study
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental health. After adjusting for sociodemographics, other drug use and childhood depression, we found no significant associations between lifetime use of psychedelics and increased likelihood of past year serious psychological distress, mental health treatment, suicidal thoughts, suicidal plans and suicide attempt, depression and anxiety. We failed to find evidence that psychedelic use is an independent risk factor for mental health problems. Psychedelics are not known to harm the brain or other body organs or to cause addiction or compulsive use; serious adverse events involving psychedelics are extremely rare. Overall, it is difficult to see how prohibition of psychedelics can be justified as a public health measure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Screening for serious mental illness in the general population
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.-L. T., Manderscheid, R. W., Walters, E. E., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.184 · Cited by 5,692
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“In a recent randomized controlled trial of psilocybin, most of the participants (67%) regarded the experience as one of the most personally significant moments in their lives (comparable to the birth of a first child) (Griffiths et al., 2006) and, furthermore, most of the participants (64%) reported improved wellbeing…”
BackgroundDrug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Kessler, R. C., Green, J. G., Gruber, M. J., Sampson, N. A., Bromet, E., Cuitan, M., Furukawa, T. A., Gureje, O., Hinkov, H., Hu, C., et al. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.310 · Cited by 1,434
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“There is increasing interest in the therapeutic use of psychedelics, especially for alcoholism (Krebs and Johansen, 2012), smoking cessation (Johnson et al., 2014), depression and other mental health problems (Baumeister et al.”
BackgroundGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Self-citationStuderus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Psychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Self-citationEffects of Schedule I drug laws on neuroscience research and treatment innovation
Nutt, D. J., King, L. A., & Nichols, D. E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3530 · Cited by 337
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · cited 2×
“Case–control and longitudinal studies have not found evidence of increased mental health problems among people who have used traditional psychedelics (peyote or ayahuasca) hundreds of times in legally recognized religious ceremonies (Bouso et al., 2012; Halpern et al., 2005).”
BackgroundRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 2×
“LSD, psilocybin and mescaline are all classical serotonergic psychedelics with main mechanism of action at the 5-HT2A receptor (Halberstadt, 2015).”
BackgroundDrug dependence: its significance and characteristics.
Eddy, N. O., Halbach, H., Isbell, H., & Seevers, M. H. (1965) · Europe PMC (PubMed Central) · Cited by 297
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
‘Visual snow’ – a disorder distinct from persistent migraine aura
Schankin, C. J., Maniyar, F. H., Digre, K. B., & Goadsby, P. J. (2014) · Brain · doi:10.1093/brain/awu050 · Cited by 232
Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010) · European Addiction Research · doi:10.1159/000317249 · Cited by 191
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D., & Pope, H. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.038 · Cited by 187
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124
Self-citationClassical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121
LSD Revisited: A Ten-Year Follow-up of Medical LSD Use
McGlothlin, W. H. (1971) · Archives of General Psychiatry · doi:10.1001/archpsyc.1971.01750070037005 · Cited by 116
Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom
Malleson, N. (1971) · British Journal of Psychiatry · doi:10.1192/bjp.118.543.229 · Cited by 111 · cited 1×
“In surveys of US, Canadian and British physicians who administered LSD to thousands of psychiatric patients in the 1950s, 1960s and 1970s, a small number of suicides and suicide attempts were reported (in people with prior suicide attempt or serious mental illness) in the year or so after taking a dose of LSD (Canada…”
BackgroundCarhart-Harris, R. L., & Nutt, D. J. (2010) · Journal of Substance Use · doi:10.3109/14659890903271624 · Cited by 105
Bruhn, J. G., Smet, P. A. G. M. D., El-Seedi, H. R., & Beck, O. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08701-9 · Cited by 104
Kelly, T. M., Cornelius, J. R., & Lynch, K. G. (2002) · Suicide and Life-Threatening Behavior · doi:10.1521/suli.32.3.301.22168 · Cited by 94
The Recanting of Earlier Reported Drug Use by Young Adults: (495622006-005)
Johnston, L. D., US Department of Health and Human Services; National Institute on Drug Abuse, & O'Malley, P. M. (1997) · PsycEXTRA Dataset · doi:10.1037/e495622006-005 · Cited by 93
Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513851 · Cited by 88
Harms associated with psychoactive substances: findings of the UK National Drug Survey
Morgan, C. J., Muetzelfeldt, L., Muetzelfeldt, M., Nutt, D. J., & Curran, H. V. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106915 · Cited by 80
Moses, L. G., & Stewart, O. C. (1989) · Western Historical Quarterly · doi:10.2307/968479 · Cited by 74
Hallock, R. M., Dean, A. C., Knecht, Z. A., Spencer, J., & Taverna, E. C. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.010 · Cited by 61
WHO expert committee on drug dependence.
(1969) · PsycEXTRA Dataset · doi:10.1037/e446692004-001 · Cited by 50
Bogenschutz, M. (2013) · Current Drug Abuse Reviews · doi:10.2174/15733998113099990002 · Cited by 47 · cited 1×
“, 2014), depression and other mental health problems (Baumeister et al., 2014; Bogenschutz, 2013; Hendricks et al., 2014).”
BackgroundHallucinogens: a forensic drug handbook
(2003) · Choice Reviews Online · doi:10.5860/choice.41-2202 · Cited by 47
PROLONGED ADVERSE REACTIONS FROM UNSUPERVISED USE OF HALLUCINOGENIC DRUGS
Kleber, H. D. (1967) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196704000-00010 · Cited by 39
Taylor, M., Mackay, K., Murphy, J., McIntosh, A. M., McIntosh, C., Anderson, S. M., & Welch, K. A. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000774 · Cited by 35
Long-term psychological effects of LSD.
McWilliams, S. A., & Tuttle, R. J. (1973) · Psychological Bulletin · doi:10.1037/h0034411 · Cited by 33
Shoval, G., Sever, J. M., Sher, L., Diller, R., Apter, A. S., Weizman, A., & Zalsman, G. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.767 · Cited by 33
Beyond Religious Freedom: Psychedelics and Cognitive Liberty
Walsh, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-40957-8_11 · Cited by 10
Bonson, K. R. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0000166.pub2 · Cited by 6
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470
“Moreover, lifetime psychedelic use has been associated with reduced odds ratio of psychological distress, suicidality and certain mental health problems in large population samples (Krebs and Johansen, 2013; Hendricks et al., 2015; Johansen and Krebs, 2015).”
Background
Metadata
- Authors
- Johansen, P.-Ø., & Krebs, T. S.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2015-03
- Volume
- 29
- Issue
- 3
- Pages
- 270-279
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2097999899
- Cited by
- 302
- References
- 44
- FWCI
- 25.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.